For decades, autoimmune disease therapy has been defined by one trade-off - suppressing the immune system to relieve symptoms. That paradigm is now breaking. The 2025 Nobel Prize in Physiology of Medicine was awarded for discoveries illuminating how the body maintains immune balance, recognizing decades of research already embedded in novel breakthrough therapeutics in development. From cell therapies inducing drug-free remission in lupus to antigen-specific approaches reprogramming pathogenic memory, the science of immune tolerance - especially through enhancing Tregs - is rapidly shifting from theoretical ambition to a clinical reality. This panel will convene leaders across biotech, pharma, and venture capital to explore how the Immunology & Inflammation field is advancing toward tolerance, how the Nobel-recognized science of immune equilibrium is reshaping R&D strategy, and what investors and partners are watching for as new therapeutic approaches redefine the future of immune medicine.